2,5-二甲基异氰酸苯酯 | 40397-98-6

• 物质功能分类: 化学试剂 - 有机试剂 - 氰酸酯/异氰酸酯
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,5-二甲基异氰酸苯酯
• 中文别名: 异氰酸2,5-二甲基苯酯
• 英文名称: 2,5-dimethylphenyl isocyanate
• 英文别名: 2-isocyanato-1,4-dimethylbenzene
• CAS: 40397-98-6
• 化学式: C₉H₉NO
• mdl: MFCD00013854
• 分子量: 147.177
• InChiKey: SOXVXJQIQVOCAY-UHFFFAOYSA-N

物化性质

• 沸点：
  210 °C(lit.)
• 密度：
  1.043 g/mL at 25 °C(lit.)
• 闪点：
  195 °F
• 稳定性/保质期：

  常规情况下不会分解，没有危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• TSCA：
  Yes
• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S26,S36
• 危险类别码：
  R42,R36/37/38,R23/25
• WGK Germany：
  3
• 海关编码：
  2929109000
• 包装等级：
  III
• 危险类别：
  6.1
• 危险品运输编号：
  UN 2206 6.1/PG 3
• 储存条件：
  密封、阴凉、干燥保存

SDS

Name:	2 5-Dimethylphenyl Isocyanate Material Safety Data Sheet
Synonym:	Benzene, 2-Isocyanato-1,4-Dimethyl-
CAS:	40397-98-6

Section 1 - Chemical Product MSDS Name:2 5-Dimethylphenyl Isocyanate Material Safety Data Sheet
Synonym:Benzene, 2-Isocyanato-1,4-Dimethyl-

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
40397-98-6	2,5-Dimethylphenyl Isocyanate	ca. 100	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis and corneal damage. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May cause skin sensitization, an allergic reaction, which becomes evident upon re-exposure to this material.
May cause irritation and dermatitis. May cause cyanosis of the extremities.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May cause liver and kidney damage.
Inhalation:
Causes respiratory tract irritation. Exposure produces central nervous system depression. Aspiration may lead to pulmonary edema. At high concentrations, isocyanates affect mucous membranes of the respiratory tract and may lead to fatal pulmonary edema. Exposure to low and often even unmeasurable isocyanate concentration results in sensitization. Can produce delayed pulmonary edema. In rare instances, exposure may cause sensitization, resulting in inflammation of the mucous membranes and in eczematous eruptions.
Chronic:
May cause liver and kidney damage. Effects may be delayed. May cause lung damage. Repeated or prolonged exposure may cause allergic reactions in sensitive individuals. Inhalation of product may aggravate existing chronic repiratory problems such as asthma, emphysema or bronchitis.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Do NOT allow victim to rub eyes or keep eyes closed.
Skin:
Get medical aid. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Wash clothing before reuse.
Ingestion:
Do not induce vomiting. Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use water spray to keep fire-exposed containers cool. Combustible liquid.
Containers may explode when heated.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use water spray to cool fire-exposed containers.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Remove all sources of ignition. Use a spark-proof tool. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Avoid contact with eyes, skin, and clothing. Empty containers retain product residue, (liquid and/or vapor), and can be dangerous. Keep container tightly closed. Keep away from heat, sparks and flame. Avoid ingestion and inhalation. Use only in a chemical fume hood. Wash clothing before reuse. Discard contaminated shoes. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose empty containers to heat, sparks or open flames.
Storage:
Keep away from sources of ignition. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 40397-98-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 210 deg C
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: 90 deg C ( 194.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9NO
Molecular Weight: 147.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, ignition sources, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 40397-98-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,5-Dimethylphenyl Isocyanate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 40397-98-6: No information available.
Canada
CAS# 40397-98-6 is listed on Canada's NDSL List.
CAS# 40397-98-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 40397-98-6 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,5-二甲基异氰酸苯酯 在 sodium hypochlorite 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 6-(2,5-dimethylphenyl)-8-methyl-3-phenyl-1-oxa-2,6,8-triazaspiro[4.4]non-2-ene-7,9-dione
  参考文献：
  名称：

  阻转异构诱导的5-甲基乙内酰脲在氧化腈环加成反应中的面部选择性

  摘要：

  N-芳基5-亚甲基乙内酰脲与氧化苯甲腈进行氧化腈环加成反应，得到具有完全区域选择性的5-螺异恶唑啉加合物。N-芳基键周围的阻转异构现象也导致这些环加成中的面部选择性。

  DOI：

  10.1021/jo2011818
• 作为产物：
  描述：

  sodium isocyanate 、 2,5-dimethylphenyl trifluoromethanesulfonate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 2-二叔丁基膦-2′,4′,6′-三异丙基-3,6-二甲氧基-1,1′-联苯 、 三(3,6-二氧杂庚基)胺 作用下， 以 甲苯 为溶剂， 反应 16.0h， 生成 2,5-二甲基异氰酸苯酯
  参考文献：
  名称：

  钯催化合成氨基甲酸芳基酯

  摘要：

  通过将醇引入钯催化的 ArX (X = Cl, OTf) 与氰酸钠的交叉偶联反应中，实现了芳基氨基甲酸酯的有效合成。在此转化中使用芳基三氟甲磺酸酯作为亲电组分允许扩大用于直接合成芳基异氰酸酯的底物范围。该方法提供了对主要氨基甲酸酯保护基团、S-硫代氨基甲酸酯和聚氨酯材料的二异氰酸酯前体的直接访问。

  DOI：

  10.1021/ol400369n

文献信息

• Inhibitors of acyl-CoA:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents
  作者：Bharat K. Trivedi、Ann Holmes、Terri L. Stoeber、C. John Blankley、W. Howard Roark、Joseph A. Picard、Mary K. Shaw、Arnold D. Essenburg、Richard L. Stanfield、Brian R. Krause

  DOI：10.1021/jm00074a011

  日期：1993.10

  We have synthesized a series of N-phenyl-N'-aralkyl and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). This intracellular enzyme is thought to be responsible for the esterification of dietary cholesterol; hence inhibition of this enzyme could reduce diet-induced hypercholesterolemia. For this series of compounds, the in vitro ACAT inhibitory activity

  我们合成了一系列的N-苯基-N'-芳烷基和N-苯基-N'-（1-苯基环烷基）脲作为酰基辅酶A：胆固醇酰基转移酶（ACAT）的抑制剂。人们认为这种细胞内酶负责饮食中胆固醇的酯化。因此抑制这种酶可以减少饮食引起的高胆固醇血症。对于这一系列化合物，通过增加苯环上2,6-取代基的体积来提高体外ACAT抑制活性。此外，我们发现芳环的间距对于ACAT抑制活性至关重要。离必需的2,6-二异丙基苯基部分5个原子的苯环对于体外活性而言是最佳的。N'-苯基部分被α取代增强了体外效能。就苯基环烷基脲而言，ACAT抑制活性与环烷基环的大小无关。从该系列类似物中，发现在高胆固醇血症动物模型中以50 mg / kg的饮食施用时，具有出色的体外抑制ACAT效力的化合物25在体内可使血浆胆固醇降低73％。在此模型中，化合物25依赖于降低血浆胆固醇剂量，并且与Lederle ACAT抑制剂CL 277082一样有效。
• [EN] ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSES D'ISOINDOLINE-1-ONE UTILISES EN TANT QU'INHIBITEURS DE KINASE
  申请人：ABBOTT LAB

  公开号：WO2004108672A1

  公开（公告）日：2004-12-16

  Compounds having the formula, (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds and compositions containing the compounds.

  具有公式(I)的化合物对于抑制蛋白酪氨酸激酶是有用的。本发明还公开了制造这些化合物的方法以及包含这些化合物的组合物。
• [EN] SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME<br/>[FR] INHIBITEURS SÉLECTIFS DE L'INFLAMMASOME NLRP3
  申请人：NODTHERA LTD

  公开号：WO2019025467A1

  公开（公告）日：2019-02-07

  The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式(I)化合物：(I)；及其药用可接受盐、药物组合物、使用方法和制备方法。所公开的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗炎症小体活性涉及的疾病，如自炎性和自身免疫疾病以及癌症。
• Potential antiatherosclerotic agents. 6. Hypocholesterolemic trisubstituted urea analogs
  作者：Vern G. DeVries、Jonathan D. Bloom、Minu D. Dutia、Andrew S. Katocs、Elwood E. Largis

  DOI：10.1021/jm00130a016

  日期：1989.10

  of the urea backbone. This study culminated in the selection of N'-(2,4-dimethylphenyl)-N-benzyl-N-n-butylurea (115) for more extensive biological evaluation. ACAT inhibitors are seen as potentially beneficial agents against hypercholesterolemia and atherosclerosis.

  一系列N，N-二烷基-N'-芳基脲是ACAT酶的抑制剂的发现导致了结构活性研究，涉及系统修饰尿素主链的三个位点。这项研究最终选择了N'-（2,4-二甲基苯基）-N-苄基-Nn-丁基脲（115），以进行更广泛的生物学评估。ACAT抑制剂被视为对抗高胆固醇血症和动脉粥样硬化的潜在有益药物。
• Thienopyranones as Kinase and Epigenetic Inhibitors
  申请人：SignalRx Pharmaceuticals, Inc.

  公开号：US20150344494A1

  公开（公告）日：2015-12-03

  The invention relates to methods of treating diseases including but not limited to, cancer non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates composing the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.

  这项发明涉及治疗疾病的方法，包括但不限于癌症、非癌性增生性疾病、败血症、自身免疫疾病、病毒感染、动脉粥样硬化、1型或2型糖尿病、肥胖症、炎症性疾病或Myc依赖性疾病，通过调节生物过程，通过抑制PI3激酶和/或溴结构域蛋白与构成给药的底物结合的生物过程，包括使用本文所定义的化合物的给药（或其药学上可接受的盐）的I-IX式。